ReviewCells2022
MgrB Mutations and Altered Cell Permeability in Colistin Resistance in
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Global prevalence of mutation in theFrontiers in microbiology · 2024Pooled it
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Clinical and Genomic Characterization of High-Risk Multidrug-ResistantMicroorganisms · 2026Article
- Pyrazolyl-Pyridine Ruthenium Complexes: A New Metallic Line of Defense Against Acinetobacter baumannii.Chembiochem : a European journal of chemical biology · 2026Article
- Genomic Insights into Chromosomal Colistin Resistance and Virulence-Resistance Convergence in MDR/XDRPathogens (Basel, Switzerland) · 2026Article
- Colistin Resistance in Gram-Negative Bacteria: Mechanisms, Transmission, and Novel Intervention Strategies.Microorganisms · 2026Review
- CRISPR/Cas diagnostics forFrontiers in bioengineering and biotechnology · 2026Review
- Extensively Drug-Resistant ST16Infection and drug resistance · 2026Article
- Phenotypic characteristics and plasmid structure differences between ST11 carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Tracking Global Transmission Dynamics of the Plasmid-MediatedMicroorganisms · 2025Article
- Epidemiological characterization of chromosome-mediated colistin resistance in hypervirulent carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2025Article
- Sequential antibiotic exposure restores antibiotic susceptibility.The Journal of antimicrobial chemotherapy · 2025Article
- Molecular characterization of colistin resistance in carbapenem-resistantMicrobiology spectrum · 2025Article
- Colistin resistance in the era of antimicrobial resistance: challenges and strategic countermeasures.Folia microbiologica · 2025Review
- Plasmid diversity in Klebsiella pneumoniae ST307 co-producing KPC plus NDM recovered during the COVID-19 pandemic.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2025Article
- Clonal Dissemination of Pandrug-ResistantInternational journal of molecular sciences · 2025Article
- Prevalence of colistin resistance in multidrug-resistantJAC-antimicrobial resistance · 2025Review
- Emerging antibiotic resistance by various novel proteins/enzymes.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Metabolic Rewiring of Bacterial Pathogens in Response to Antibiotic Pressure-A Molecular Perspective.International journal of molecular sciences · 2025Review
- Determination of Colistin Resistance in Clinical Isolates from Healthcare Facilities in Mthatha and Surrounding Areas.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been a resurgence in the clinical use of polymyxin antibiotics such as colistin due to the limited treatment options for infections caused by carbapenem-resistant Enterobacterales (CRE). However, this last-resort antibiotic is currently confronted with challenges which include the emergence of chromosomal and plasmid-borne colistin resistance. Colistin resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.